We apologize if your country is not currently listed. Please feel free to contact us through our global page and we will do our best to assist you.
In order to support research and science, Wörwag Pharma announces the 11th Dr. Fritz-Wörwag Research Prize 2024/25.
Böblingen, February 22, 2024 – Wörwag Pharma closed the 2023 financial year with an organic sales growth of 7.6 percent – despite the tense situation…
Böblingen, January 22, 2024 – With the renaming of the most recent investment Mauermann Arzneimittel GmbH & Co. KG, Wörwag Pharma is taking the next…
Böblingen, September 19, 2023 – Wörwag Pharma is taking over contract manufacturer Mauermann-Arzneimittel KG with immediate effect. The…
Böblingen, March 16, 2023 – The Böblingen-based pharmaceutical and family-owned company Wörwag Pharma closed the 2022 financial year with an increase…
Böblingen, February 13, 2023 – The shareholders' meeting of the Wörwag Pharma Group has elected a new Advisory Board: With Konstantin von Alvensleben…
Böblingen, February 17, 2022 – The Boeblingen-based family-owned company Wörwag Pharma invested in several strategic milestones in 2021 and…
In order to support science and research, Wörwag Pharma has awarded the 10th Fritz Wörwag Research Prize this year. The prize rewards new research…
Just in time for the anniversary year, Wörwag Pharma presents itself with a new logo: traditional yet innovative, rooted yet globally oriented.
Böblingen/Lódz – German pharmaceutical company Wörwag Pharma GmbH & Co. KG announces the acquisition of Sensilab, contract manufacturer and…